| Nome |
# |
|
Leucocyte classification for leukaemia detection using image processing techniques, file e2f56ed4-7e11-3eaf-e053-3a05fe0a5d97
|
1.650
|
|
Ethical concerns surrounding the conception of an HLA compatible child for medical purposes, file e2f56ed3-bff1-3eaf-e053-3a05fe0a5d97
|
261
|
|
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study, file e2f56ed9-0ab3-3eaf-e053-3a05fe0a5d97
|
260
|
|
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis, file e2f56ed4-bff5-3eaf-e053-3a05fe0a5d97
|
215
|
|
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation, file e2f56ed7-557d-3eaf-e053-3a05fe0a5d97
|
214
|
|
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review, file e2f56ed9-7f13-3eaf-e053-3a05fe0a5d97
|
203
|
|
The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L, file e2f56ed9-bbe7-3eaf-e053-3a05fe0a5d97
|
203
|
|
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia, file e2f56ed7-f253-3eaf-e053-3a05fe0a5d97
|
196
|
|
Systemic Mastocytosis with Associated Primary Myelofibrosis, file e2f56ed9-1ccc-3eaf-e053-3a05fe0a5d97
|
183
|
|
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma, file e2f56ed5-259b-3eaf-e053-3a05fe0a5d97
|
174
|
|
What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics, file e2f56ed5-ca06-3eaf-e053-3a05fe0a5d97
|
174
|
|
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP, file e2f56ed9-39c2-3eaf-e053-3a05fe0a5d97
|
174
|
|
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research, file e2f56ed9-0c8c-3eaf-e053-3a05fe0a5d97
|
168
|
|
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report, file e2f56ed4-9f67-3eaf-e053-3a05fe0a5d97
|
165
|
|
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission, file e2f56ed7-e71a-3eaf-e053-3a05fe0a5d97
|
161
|
|
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice, file e2f56ed8-33f1-3eaf-e053-3a05fe0a5d97
|
159
|
|
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation, file e2f56ed6-a2b9-3eaf-e053-3a05fe0a5d97
|
153
|
|
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients, file e2f56ed5-26ab-3eaf-e053-3a05fe0a5d97
|
136
|
|
null, file e2f56ed6-85e4-3eaf-e053-3a05fe0a5d97
|
126
|
|
Myocardial iron overload assessment by T2*magnetic resonance imaging in adult transfusion dependent patients with acquired anemias, file e2f56ed3-91f2-3eaf-e053-3a05fe0a5d97
|
123
|
|
Immunological deregulation in classic hodgkin lymphoma, file e2f56ed4-9825-3eaf-e053-3a05fe0a5d97
|
123
|
|
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis, file e2f56ed9-5b72-3eaf-e053-3a05fe0a5d97
|
120
|
|
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients, file e2f56ed3-a4ee-3eaf-e053-3a05fe0a5d97
|
110
|
|
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors, file e2f56ed9-1277-3eaf-e053-3a05fe0a5d97
|
110
|
|
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma, file e2f56ed5-259e-3eaf-e053-3a05fe0a5d97
|
109
|
|
Thresholds for clinical importance were defined for the EORTC CAT Core - an adaptive measure of core quality of life domains in oncology clinical practice and research, file e2f56ed8-a801-3eaf-e053-3a05fe0a5d97
|
108
|
|
null, file e2f56ed6-d454-3eaf-e053-3a05fe0a5d97
|
102
|
|
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis, file e2f56eda-a5bf-3eaf-e053-3a05fe0a5d97
|
100
|
|
Health related quality of life in Middle Eastern children with beta-thalassemia, file e2f56ed5-2763-3eaf-e053-3a05fe0a5d97
|
98
|
|
Conditioning Regimens in Patients with β-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review, file e2f56eda-99eb-3eaf-e053-3a05fe0a5d97
|
97
|
|
Reassessing the approach to informed consent: The case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients, file e2f56ed8-4a84-3eaf-e053-3a05fe0a5d97
|
96
|
|
Efficacia e tollerabilità di nilotinib in terza linea in un paziente anziano con LMC = Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML, file e2f56ed3-8f25-3eaf-e053-3a05fe0a5d97
|
93
|
|
Ruxolitinib therapy and telomere length in myelofibrosis, file e2f56ed5-69cb-3eaf-e053-3a05fe0a5d97
|
91
|
|
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study, file 2a0b3adc-6d97-477f-855a-77611a8b05b4
|
90
|
|
Daunorubicin, cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte infusion for extramedullary relapse of acute myeloid leukemia after hematopoietic stem cell transplantation, file e2f56ed3-90b3-3eaf-e053-3a05fe0a5d97
|
89
|
|
Health related quality of life in patients with onco-hematological diseases, file e2f56ed9-6b04-3eaf-e053-3a05fe0a5d97
|
87
|
|
null, file e2f56ed8-cddb-3eaf-e053-3a05fe0a5d97
|
86
|
|
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation, file e2f56ed9-85cd-3eaf-e053-3a05fe0a5d97
|
86
|
|
Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript, file e2f56ed3-a530-3eaf-e053-3a05fe0a5d97
|
83
|
|
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?, file e2f56ed9-40a6-3eaf-e053-3a05fe0a5d97
|
83
|
|
Early Death in Two Patients with Acute Promyelocytic Leukemia Presenting the bcr3 Isoform, FLT3-ITD Mutation, and Elevated WT1 Level, file e2f56ed3-ac91-3eaf-e053-3a05fe0a5d97
|
81
|
|
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021, file ee0d7c62-9066-4d58-8d5d-5c95cd08d812
|
81
|
|
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting, file e2f56ed8-ef9c-3eaf-e053-3a05fe0a5d97
|
80
|
|
The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia, file e6890d92-d86e-49bb-8212-c7e44f4045fb
|
77
|
|
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome, file 7958795b-ba72-4cbb-840a-58bc928c9c4f
|
75
|
|
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia, file e2f56ed9-6f98-3eaf-e053-3a05fe0a5d97
|
71
|
|
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors, file e2f56ed9-28a7-3eaf-e053-3a05fe0a5d97
|
64
|
|
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors, file e2f56ed9-f5fc-3eaf-e053-3a05fe0a5d97
|
59
|
|
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination, file e2f56eda-47c7-3eaf-e053-3a05fe0a5d97
|
58
|
|
Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts, file e2f56ed9-aa1f-3eaf-e053-3a05fe0a5d97
|
54
|
|
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine, file 7759f025-e64b-4a33-88f3-365f00c2448c
|
52
|
|
Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation, file dbf54084-84e9-44f6-9349-5999f63ea1e1
|
48
|
|
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors, file 42c6f59c-53c2-42ff-b679-5ea7f559e316
|
45
|
|
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura, file 9a3fc0a3-7f6e-4c46-990f-986d0f6bfd12
|
45
|
|
Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone, file e2f56ed9-4fb8-3eaf-e053-3a05fe0a5d97
|
43
|
|
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies", file 04bcbb3f-b3d9-4887-aeb6-85102ead79aa
|
39
|
|
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey, file 987b30e0-dc85-4c6c-812a-265735902104
|
39
|
|
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia, file 7784ebad-6ea6-45cf-b7e9-e5956fdd35ae
|
32
|
|
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia, file fcf4e2e9-0624-4cd1-850f-0334e6deb828
|
30
|
|
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network, file e2f56eda-413c-3eaf-e053-3a05fe0a5d97
|
29
|
|
Unrelated bone marrow transplantation in Thalassemia. The experience of the Italian Bone Marrow transplant Group (GITMO), file e2f56ed3-baa5-3eaf-e053-3a05fe0a5d97
|
26
|
|
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart, file e2f56ed9-032c-3eaf-e053-3a05fe0a5d97
|
26
|
|
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia, file 8d50acfd-77ab-4167-9cc4-a2c6b96ebbb0
|
22
|
|
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?, file b67af45a-a58e-4652-9a94-2283bb1837c2
|
20
|
|
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy, file ea9d8f24-a1e2-44c4-957b-154a0193f5a0
|
19
|
|
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome, file e2f56eda-23da-3eaf-e053-3a05fe0a5d97
|
17
|
|
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome, file e2f56eda-3a15-3eaf-e053-3a05fe0a5d97
|
16
|
|
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study, file 41f599de-d502-444a-a1fd-0c626d718ce6
|
15
|
|
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials, file e2f56eda-8b6b-3eaf-e053-3a05fe0a5d97
|
15
|
|
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA, file 42d453ce-c2ae-47ea-bdaf-c73a20962d1e
|
14
|
|
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation, file e2f56ed3-b7c0-3eaf-e053-3a05fe0a5d97
|
14
|
|
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study, file e2f56ed9-bcc1-3eaf-e053-3a05fe0a5d97
|
14
|
|
Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation, file 6c92ef65-6cb6-4976-a0b4-7e42f2a77e5e
|
13
|
|
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity, file e2f56ed8-ecbf-3eaf-e053-3a05fe0a5d97
|
13
|
|
Adherence to treatment in patients with solid and hematological cancers. Could spiritual and psychological support facilitate optimal adherence?, file 845cd91e-29bc-4e13-8e22-884d467d2844
|
12
|
|
International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia, file e2f56ed6-f4c9-3eaf-e053-3a05fe0a5d97
|
12
|
|
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib, file 0b704f22-b447-4df4-8d58-bc48706890bb
|
11
|
|
Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation, file 2d884c2d-eb73-444b-ba1e-7d5fb3f172ce
|
11
|
|
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients, file e2f56ed4-945d-3eaf-e053-3a05fe0a5d97
|
10
|
|
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?, file e2f56ed4-9d57-3eaf-e053-3a05fe0a5d97
|
10
|
|
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia, file e2f56eda-cef1-3eaf-e053-3a05fe0a5d97
|
10
|
|
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis, file 5c8ad2a4-2f3b-49e8-ad21-4f57669861d3
|
9
|
|
Low adherence to therapy and co-morbid depressive episodes are independent determinants of early death in people with cancer, file 1b308f47-84ea-4e3a-b59a-5e6f789f085e
|
8
|
|
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders?, file e2f56ed9-a437-3eaf-e053-3a05fe0a5d97
|
8
|
|
Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis, file e2f56eda-914c-3eaf-e053-3a05fe0a5d97
|
8
|
|
International validation of a health-related quality of life questionnaire for Hodgkin Lymphoma: the EORTC QLQ-HL27, file cec3012e-27dc-4447-ba06-75c6c04afcfc
|
7
|
|
Matching for extended haplotypes and DPB1 alleles improves outcome of unrelated bone marrow transplantation in Thalassemia, file e2f56ed3-a2df-3eaf-e053-3a05fe0a5d97
|
7
|
|
Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia, file e2f56ed3-c5cc-3eaf-e053-3a05fe0a5d97
|
7
|
|
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia, file e2f56ed6-bf64-3eaf-e053-3a05fe0a5d97
|
7
|
|
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors, file e2f56ed8-74a1-3eaf-e053-3a05fe0a5d97
|
7
|
|
Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis, file 95090077-81c9-40b8-b191-f4ce7db04192
|
6
|
|
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients, file e2f56ed3-c8e2-3eaf-e053-3a05fe0a5d97
|
6
|
|
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis, file e2f56ed5-2944-3eaf-e053-3a05fe0a5d97
|
6
|
|
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis, file e2f56ed5-2994-3eaf-e053-3a05fe0a5d97
|
6
|
|
null, file e2f56ed6-d466-3eaf-e053-3a05fe0a5d97
|
6
|
|
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia, file e2f56ed8-c85c-3eaf-e053-3a05fe0a5d97
|
6
|
|
Bone marrow homing and engraftment defects of human hematopoietic stem and progenitor cells, file e2f56eda-3b72-3eaf-e053-3a05fe0a5d97
|
6
|
|
A real-world study on clofarabine and cytarabine combination in patients with relapsed/refractory acute myeloid leukemia, file e2f56eda-95ec-3eaf-e053-3a05fe0a5d97
|
6
|
|
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help, file 51224597-31e3-4974-ab30-3319d210f12c
|
5
|
|
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study, file a7968834-81d0-4e76-9d79-26fe55b954ed
|
5
|
| Totale |
8.607 |